Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions

Young Hak Kim, Seong Wook Park, Cheol Whan Lee, Myeongki Hong, Hyeon Cheol Gwon, Yangsoo Jang, Myoung Mook Lee, Bon Kwon Koo, Dong Joo Oh, Ki Bae Seung, Seung Jae Tahk, Junghan Yoon, Seung Jung Park

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Objective: This study compared the efficacy of the sirolimus-eluting stent (SES), the paclitaxel-eluting stent (PES), and the bare metal stent (BMS) for long coronary lesions. Background: The outcome of drug-eluting stent (DES) implantation in long coronary lesions remains unclear. Methods: The study involved 527 patients with de novo long coronary lesions (≥24 mm), which were treated with long (≥28 mm) SESs (223 lesions), PESs (194 lesions), or BMSs (201 lesions). Results: Lesions in the SES (36.0 ± 14.9 mm, P < 0.001) and PES (36.3 ± 14.5 mm, P < 0.001) groups were longer than those in the BMS group (32.0 ± 12.3 mm), meaning the two DES groups had longer stented segments than did the BMS group. Six-month angiographic follow-up showed the SES (9.3%, P < 0.001) and PES (21.3%, P < 0.001) groups had lower in-segment restenosis rates than that of the BMS group (42.5%). The rate of major adverse cardiac events (MACE) including death, myocardial infarction, and target lesion revascularization at 9 months was higher in the BMS group (26.6%) than that in the SES (13.0%, P < 0.001) and PES (15.7%, P < 0.001) groups. Posthoc analysis of the two DES groups showed that the in-segment restenosis rate was lower for the SES than that for the PES group (P = 0.002), while the MACE rate was similar. Conclusions: The use of DESs for long coronary lesions appears to be safe and more effective than the use of BMSs in terms of restenosis and adverse clinical events. SES use was associated with lower late luminal loss and a lower angiographic restenosis rate compared with PES use.

Original languageEnglish
Pages (from-to)181-187
Number of pages7
JournalCatheterization and Cardiovascular Interventions
Volume67
Issue number2
DOIs
Publication statusPublished - 2006 Feb 1

Fingerprint

Sirolimus
Paclitaxel
Stents
Metals
Therapeutics
Drug-Eluting Stents

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Young Hak ; Park, Seong Wook ; Lee, Cheol Whan ; Hong, Myeongki ; Gwon, Hyeon Cheol ; Jang, Yangsoo ; Lee, Myoung Mook ; Koo, Bon Kwon ; Oh, Dong Joo ; Seung, Ki Bae ; Tahk, Seung Jae ; Yoon, Junghan ; Park, Seung Jung. / Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. In: Catheterization and Cardiovascular Interventions. 2006 ; Vol. 67, No. 2. pp. 181-187.
@article{7e19857de69b4b7bbdb69eff05f580a2,
title = "Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions",
abstract = "Objective: This study compared the efficacy of the sirolimus-eluting stent (SES), the paclitaxel-eluting stent (PES), and the bare metal stent (BMS) for long coronary lesions. Background: The outcome of drug-eluting stent (DES) implantation in long coronary lesions remains unclear. Methods: The study involved 527 patients with de novo long coronary lesions (≥24 mm), which were treated with long (≥28 mm) SESs (223 lesions), PESs (194 lesions), or BMSs (201 lesions). Results: Lesions in the SES (36.0 ± 14.9 mm, P < 0.001) and PES (36.3 ± 14.5 mm, P < 0.001) groups were longer than those in the BMS group (32.0 ± 12.3 mm), meaning the two DES groups had longer stented segments than did the BMS group. Six-month angiographic follow-up showed the SES (9.3{\%}, P < 0.001) and PES (21.3{\%}, P < 0.001) groups had lower in-segment restenosis rates than that of the BMS group (42.5{\%}). The rate of major adverse cardiac events (MACE) including death, myocardial infarction, and target lesion revascularization at 9 months was higher in the BMS group (26.6{\%}) than that in the SES (13.0{\%}, P < 0.001) and PES (15.7{\%}, P < 0.001) groups. Posthoc analysis of the two DES groups showed that the in-segment restenosis rate was lower for the SES than that for the PES group (P = 0.002), while the MACE rate was similar. Conclusions: The use of DESs for long coronary lesions appears to be safe and more effective than the use of BMSs in terms of restenosis and adverse clinical events. SES use was associated with lower late luminal loss and a lower angiographic restenosis rate compared with PES use.",
author = "Kim, {Young Hak} and Park, {Seong Wook} and Lee, {Cheol Whan} and Myeongki Hong and Gwon, {Hyeon Cheol} and Yangsoo Jang and Lee, {Myoung Mook} and Koo, {Bon Kwon} and Oh, {Dong Joo} and Seung, {Ki Bae} and Tahk, {Seung Jae} and Junghan Yoon and Park, {Seung Jung}",
year = "2006",
month = "2",
day = "1",
doi = "10.1002/ccd.20586",
language = "English",
volume = "67",
pages = "181--187",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "2",

}

Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. / Kim, Young Hak; Park, Seong Wook; Lee, Cheol Whan; Hong, Myeongki; Gwon, Hyeon Cheol; Jang, Yangsoo; Lee, Myoung Mook; Koo, Bon Kwon; Oh, Dong Joo; Seung, Ki Bae; Tahk, Seung Jae; Yoon, Junghan; Park, Seung Jung.

In: Catheterization and Cardiovascular Interventions, Vol. 67, No. 2, 01.02.2006, p. 181-187.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions

AU - Kim, Young Hak

AU - Park, Seong Wook

AU - Lee, Cheol Whan

AU - Hong, Myeongki

AU - Gwon, Hyeon Cheol

AU - Jang, Yangsoo

AU - Lee, Myoung Mook

AU - Koo, Bon Kwon

AU - Oh, Dong Joo

AU - Seung, Ki Bae

AU - Tahk, Seung Jae

AU - Yoon, Junghan

AU - Park, Seung Jung

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Objective: This study compared the efficacy of the sirolimus-eluting stent (SES), the paclitaxel-eluting stent (PES), and the bare metal stent (BMS) for long coronary lesions. Background: The outcome of drug-eluting stent (DES) implantation in long coronary lesions remains unclear. Methods: The study involved 527 patients with de novo long coronary lesions (≥24 mm), which were treated with long (≥28 mm) SESs (223 lesions), PESs (194 lesions), or BMSs (201 lesions). Results: Lesions in the SES (36.0 ± 14.9 mm, P < 0.001) and PES (36.3 ± 14.5 mm, P < 0.001) groups were longer than those in the BMS group (32.0 ± 12.3 mm), meaning the two DES groups had longer stented segments than did the BMS group. Six-month angiographic follow-up showed the SES (9.3%, P < 0.001) and PES (21.3%, P < 0.001) groups had lower in-segment restenosis rates than that of the BMS group (42.5%). The rate of major adverse cardiac events (MACE) including death, myocardial infarction, and target lesion revascularization at 9 months was higher in the BMS group (26.6%) than that in the SES (13.0%, P < 0.001) and PES (15.7%, P < 0.001) groups. Posthoc analysis of the two DES groups showed that the in-segment restenosis rate was lower for the SES than that for the PES group (P = 0.002), while the MACE rate was similar. Conclusions: The use of DESs for long coronary lesions appears to be safe and more effective than the use of BMSs in terms of restenosis and adverse clinical events. SES use was associated with lower late luminal loss and a lower angiographic restenosis rate compared with PES use.

AB - Objective: This study compared the efficacy of the sirolimus-eluting stent (SES), the paclitaxel-eluting stent (PES), and the bare metal stent (BMS) for long coronary lesions. Background: The outcome of drug-eluting stent (DES) implantation in long coronary lesions remains unclear. Methods: The study involved 527 patients with de novo long coronary lesions (≥24 mm), which were treated with long (≥28 mm) SESs (223 lesions), PESs (194 lesions), or BMSs (201 lesions). Results: Lesions in the SES (36.0 ± 14.9 mm, P < 0.001) and PES (36.3 ± 14.5 mm, P < 0.001) groups were longer than those in the BMS group (32.0 ± 12.3 mm), meaning the two DES groups had longer stented segments than did the BMS group. Six-month angiographic follow-up showed the SES (9.3%, P < 0.001) and PES (21.3%, P < 0.001) groups had lower in-segment restenosis rates than that of the BMS group (42.5%). The rate of major adverse cardiac events (MACE) including death, myocardial infarction, and target lesion revascularization at 9 months was higher in the BMS group (26.6%) than that in the SES (13.0%, P < 0.001) and PES (15.7%, P < 0.001) groups. Posthoc analysis of the two DES groups showed that the in-segment restenosis rate was lower for the SES than that for the PES group (P = 0.002), while the MACE rate was similar. Conclusions: The use of DESs for long coronary lesions appears to be safe and more effective than the use of BMSs in terms of restenosis and adverse clinical events. SES use was associated with lower late luminal loss and a lower angiographic restenosis rate compared with PES use.

UR - http://www.scopus.com/inward/record.url?scp=32544432245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32544432245&partnerID=8YFLogxK

U2 - 10.1002/ccd.20586

DO - 10.1002/ccd.20586

M3 - Article

C2 - 16400663

AN - SCOPUS:32544432245

VL - 67

SP - 181

EP - 187

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 2

ER -